Peptides and methods for the control of obesity

Details Peptides and methods for the control of obesity Peptides and methods for the control of obesity

2008-05-06

2008-05-06

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S330000

Reexamination Certificate

active

07368433

ABSTRACT:
The subject invention provides novel peptides for use in treating mammals to control appetite and obesity. Disclosed is a peptide derivative having the formula:in-line-formulae description="In-line Formulae" end="lead"?X1-Z-Q-arg-trp-NH2in-line-formulae description="In-line Formulae" end="tail"?wherein: X1is an acyl group, Z is amino-2-naphthyl-carboxylic acid or histidine, Q is (D)phenylalanine or p-iodo-(D)phenylalanine, or a pharmacologically acceptable salt, complex or derivative thereof, the peptide derivative having melanocortin-4 receptor agonist activity.

REFERENCES:
patent: 5420109 (1995-05-01), Suto et al.
patent: 5726156 (1998-03-01), Girten et al.
patent: 5741774 (1998-04-01), Girten et al.
patent: 5760001 (1998-06-01), Girten et al.
patent: 5786332 (1998-07-01), Girten et al.
patent: 5888969 (1999-03-01), Girten et al.
patent: 5908609 (1999-06-01), Lee et al.
patent: 6245738 (2001-06-01), Suto et al.
patent: 6284735 (2001-09-01), Girten et al.
patent: 6613874 (2003-09-01), Mazur et al.
patent: 7034004 (2006-04-01), Haskell-Luevano et al.
patent: 2001/0056179 (2001-12-01), Chen et al.
patent: WO 97/47316 (1997-12-01), None
Al-Obeidi, F. et al. “Design of a New Class of Superpotent Cyclic α-Melanotropins Based on Quenched Dynamic Simulations”,J. Am. Chem. Soc., 1989, pp. 3413-3416, vol. 111, No. 9.
Al-Obeidi, F. et al. “Potent and Prolonged Acting Cyclic Lactam Analogues of α-Melanotropin: Design Based on Molecular Dynamics”J. Med. Chem., 1989, pp. 2555-2561, vol. 32, No. 12.
Bednarek, M.A. et al. “Analogs of Lactam Derivatives of α-Melanotropin with Basic and Acidic Residues”,Biochemical and Biophysical Research Communications, 2000, pp. 23-28, vol. 272.
Bednarek, M.A. et al. “Analogs of MTII, Lactan Derivatives of α-Melanotropin, Modified at the N-Terminus, and their Selectivity at Human Melanocortin Receptors 3, 4, and 5”,Biochem. Biophys. Res. Commun., 1999, pp. 209-213, vol. 261, No. 1.
Bednarek, M.A. et al. “Potent and Selective Peptide Agonists of α-Melanotropin Action at Human Melanocortin Receptor 4: Their Synthesis and Biological Evaluation in Vitro”,Biochem. Biophys. Res. Commun., 2001, pp. 641-645, vol. 286, No. 3.
Benoit, S.C. et al. “A Novel Selective Melanocortin-4 Receptor Agonist Reduces Food Intake in Rats and Mice Without Producing Aversive Consequences”,J. Neurosci., 2000, pp. 3442-3448, vol. 20, No. 9.
Butler, A.A. et al. “A Unique Metabolic Syndrome Causes Obesity in the Melanocortin-3 Receptor-Deficient Mouse”,Endocrinology, 2000, pp. 3518-3521, vol. 141, No. 9.
Chen, A.S. et al. “Inactivation of the Mouse Melanocortin-3 Receptor Results in Increased Fat Mass and Reduced Lean Body Mass”,Nat. Genet., 2000, pp. 97-102, vol. 26.
Chen, W. et al. “Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides”,Cell, 1997, pp. 789-798, vol. 91.
Colditz, G. Economic Costs of Obesity1-3,Am. J. Clin. Nutr., 1992, pp. 503S-507S, vol. 55.
Danho, W. et al. “Highly Selective Cyclic Peptides for Human Melanocortin-4 Receptor (MC-4R): Design, Synthesis, Bioactive Conformation, and Pharmacological Evaluation as an Anti-obesity Agent”,Proceedings of the 2ndInternational/ 17thAmerican Peptide Symposium, 2001, pp. 701-703.
Ezzell, C. et al. “Fat Times for Obesity Research: Tons of New Information, But How Does it All Fit Together”,J. NIH Res., 1995, pp. 39-43, vol. 7.
Fan, W. et al. “Role of Melanocortinergic Neurons in Feeding and the Agouti Obesity Syndrome”,Nature, 1997, pp. 165-168, vol. 385.
Flier, J.S. “Leptin Expression and Action: New Experimental Paradigms”,Proc. Natl. Acad. Sci. USA, 1997, pp. 4242-4245, vol. 94.
Gantz, I. et al. “Molecular Cloning, Expression, and Gene Localization of a Fourth Melanocortin Receptor”,J. Biol. Chem., 1993, pp. 15174-15179, vol. 268, No. 20.
Gantz, I. et al. “T. Molecular Cloning of a Novel Melanocortin Receptor”,J. Biol. Chem., 1993, pp. 8246-8250, vol. 268, No. 11.
Greenway, F. et al. “Surgery for Obesity”,Endo. Metab. Clin. N. Ameri., 1996, pp. 1005-1027, vol. 25, No. 4
Grieco, P. et al. “Design and Synthesis of Highly Potent and Selective Melanotropin Analogues of SHU9119 Modified at Position 6”,Biochemical and Biophysical Research Communications, 2002, pp. 1075-1080, vol. 292, No. 4.
Grieco, P. et al. “New Dimensions in the Design of Potent and Receptor Selective Melanotropin Analogues”,In Peptides for the New Millennium, Proceedings of the 16thAmerican Peptide Symposium, 2000, pp. 541-542.
Gura, T. “Obesity Sheds its Secrets”,Science, 1997, pp. 751-753, vol. 275.
Haskell-Luevano, C. et al. “Characterization of Melanocortin NDP-MSH Agonist Peptide Fragments at the Mouse Central and Peripheral Melanocortin Receptors”,J. Med. Chem., 2001, pp. 2247-2252, vol. 44.
Haskell-Luevano, C. et al. “Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R”,J. Med. Chem., 1997, pp. 2133-2139, vol. 40.
Haskell-Luevano, C. et al. “Structure Activity Studies of the Melanocortin-4 Receptor by In Vitro Mutagenesis: Identification of Agouti-Related Protein (AGRP), Melanocortin Agonist and Synthetic Peptide Antagonist Interaction Determinants”,Biochemistry, 2001, pp. 6164-6179, vol. 40, No. 20.
Haskell-Luevano, C. et al. “Truncation Studies of α-Melanotropin Peptides Identify Tripeptide Analogues Exhibiting Prolonged Agonist Bioactivity”,Peptides, 1996, pp. 995-1002, vol. 17, No. 6.
Holder, J.R. et al. “Structure-Activity Relationships of the Melanocortin Tetrapeptide Ac-His-Dphe-Arg-Trp-NH2at Mouse Melanocortin Receptors. Part 1 Modifications at the His Position”,J. Med. Chem., 2002, pp. 2801-2810, vol. 45.
Holder, J.R. et al. “Structure-Activity Relationships of the Melanocortin Tetrapeptide Ac-His-Dphe-Arg-Trp-NH2at Mouse Melanocortin Receptors: Part 2 Modifications at the Phe Position”,J. Med. Chem., 2002, pp. 3073-3081, vol. 45.
Hruby, V.J. et al. “Cyclic Lactam α-Melanotropin Analogues of Ac-Nle4-c(Asp5,Dphe7, Lys10)-α-MSH(4-10)-NH2with Bulky Aromatic Amino Acids at Position 7 Show High Antagonist Potency and Selectivity at Specific Melanocortin Receptors”,J. Med. Chem., 1995, pp. 3454-3461, vol. 38, No. 18.
Huszar, D. et al. “Targeted Disruption of the Melanocortin-4 Receptor Results in Obesity in Mice”,Cell, Jan. 1997, pp. 131-141, vol. 88.
Kaiser, E. et al. “Color Test for Detection of Free Terminal Amino Groups in the Solid-Phase Synthesis of Peptides”,Anal. Biochem., 1970, pp. 595-598, vol. 34.
Kavarano, M.J. et al. “The Development of a Novel Highly Selective and Potent Agonist for Human Melanocortin-4 Receptor”Proceedings of the 2ndInternational/ 17thAmerican Peptide Symposium, 2001, pp. 708-709.
Lee, I. et al. “Change in Body Weight and Longevity”,JAMA, 1992, pp. 2045-2049, vol. 268, No. 15.
Long, S. et al. “Weight Loss in Severely Obese Subjects Prevents the Progression of Impaired Glucose Tolerance to Type II Diabetes”,Diabetes Care, 1994, pp. 372-375, vol. 17, No. 5.
Lu, D. et al. “Agouti Protein is an Antagonist of the Melanocyte-Stimulating-Hormone Receptor”,Nature, 1994, pp. 799-802, vol. 371.
McGinnis, J. et al. “Actual Causes of Death in the United States”, 1993, MA., pp. 2207-2212, vol. 270, No. 18.
Mountjoy, K.G. et al. “Localization of the Melanocortin-4 Receptor (MC4-R) in Neuroendocrine and Automated Control Circuits in the Brain”,Mol. Endo., 1994, pp. 1298-1308, vol. 8.
National Task Force on Obesity. “Long-Term Pharmacotherapy in the Management of Obesity”,JAMA, 1996, pp. 1907-1915, vol. 276, No. 23.
NIH Technology Assessment Conference Panel. “Gastrointest

Affiliated with

Also associated with

Rating

Peptides and methods for the control of obesity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides and methods for the control of obesity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides and methods for the control of obesity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2763211